 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
NanoCor Therapeutics, Inc. (NanoCor) is developing a therapeutic for the treatment of Chronic Heart Failure (CHF) that treats the disease at the molecular level. Using our proprietary Biological Nano Particle (BNP) technology platform and a patent-protected gene, NanoCor will provide the 15 million patients currently suffering from CHF with an effective, minimally invasive, economic and safe alternative treatment. The company is based on the scientific work of Professor R. Jude Samulski, Director of Gene Therapy at the University of North Carolina at Chapel Hill, Professor Evangelia Kranias of the University of Cincinnati, and Professor Roger Hajjar of Mt. Sinai School of Medicine.
|
||||
| About Nanocor | ||||
|
|
||||
| Contact Us | ||||
|
||||
870 Martin Luther King Jr. Blvd.
NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a non-invasive treatment for these patients and advance the current standard of care.